RP
Repare Therapeutics Inc.
RPTX · NASDAQ
$2.58 +0.19% (+$0.01)
Market Cap $110.5M
P/E Ratio -
Div. Yield -
ROE 57.56%
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
3/9Valuation
50 /100
Fair P/S 9.31x
P/B 0.96x
P/E N/A
Growth
-
N/A EPS growth N/A
Book val. growth N/A
Rev. growth N/A
Profitability
20 /100
Weak Gross margin 86.18%
FCF margin 590.97%
Net margin 608.26%
Quality
1 /100
Poor ROIC 65.98%
Asset turnover 0.09x
ROE 57.56%
Debt
94 /100
Low Debt/Equity 0.00x
Net debt/EBITDA 1.01x
Current ratio 10.71x
Stability
34 /100
Moderate Beta 0.96x
Profitable years 0
EPS volatility 98.83%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about RPTX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Steve Forte
Employees
129
Headquarters
Montreal